Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.
Identifieur interne : 001459 ( Ncbi/Merge ); précédent : 001458; suivant : 001460Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.
Auteurs : M. Contin [Italie] ; R. Riva ; P. Martinelli ; A. BaruzziSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1992.
English descriptors
- KwdEn :
- Adult, Benserazide (administration & dosage), Benserazide (adverse effects), Benserazide (pharmacokinetics), Carbidopa (administration & dosage), Carbidopa (adverse effects), Carbidopa (pharmacokinetics), Drug Therapy, Combination, Female, Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (pharmacokinetics), Male, Middle Aged, Motor Skills (drug effects), Motor Skills (physiology), Neurologic Examination (drug effects), Parkinson Disease (blood), Parkinson Disease (drug therapy), Reaction Time (drug effects), Reaction Time (physiology).
- MESH :
- chemical , administration & dosage : Benserazide, Carbidopa, Levodopa.
- chemical , adverse effects : Benserazide, Carbidopa, Levodopa.
- chemical , pharmacokinetics : Benserazide, Carbidopa, Levodopa.
- blood : Parkinson Disease.
- drug effects : Motor Skills, Neurologic Examination, Reaction Time.
- drug therapy : Parkinson Disease.
- physiology : Motor Skills, Reaction Time.
- Adult, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Abstract
The potential difference in the concentration-effect relationship of oral sequential doses of levodopa was explored in six Parkinsonian patients with complex fluctuating response. These patients showed "wearing-off phenomena" characterized by a transient worsening of motor function at the end of the first morning dose response to below baseline values and complained of a progressive reduction of levodopa effect during the day. A first standard levodopa dose was given in the morning, after an overnight fast and levodopa withdrawal. A second equal levodopa dose was administered immediately at the end of the first dose deterioration phase. Postimprovement worsening of motor response was also observed after the second levodopa dose in all patients. No significant difference in the pharmacokinetics of levodopa or in duration or magnitude of motor response could be appreciated between the two doses. These results further support the suggestion that, under controlled dietary conditions, plasma levodopa levels and effects relationship is reproducible between doses. Moreover, even when transient deterioration of motor function occurs between levodopa doses, the central dopaminergic system appears to remain responsive to the drug.
DOI: 10.1002/mds.870070310
PubMed: 1620142
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004D31
- to stream PubMed, to step Curation: 004D31
- to stream PubMed, to step Checkpoint: 004D35
Links to Exploration step
pubmed:1620142Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.</title><author><name sortKey="Contin, M" sort="Contin, M" uniqKey="Contin M" first="M" last="Contin">M. Contin</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Neuropharmacology, University of Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Laboratory of Neuropharmacology, University of Bologna</wicri:regionArea><wicri:noRegion>University of Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Riva, R" sort="Riva, R" uniqKey="Riva R" first="R" last="Riva">R. Riva</name></author><author><name sortKey="Martinelli, P" sort="Martinelli, P" uniqKey="Martinelli P" first="P" last="Martinelli">P. Martinelli</name></author><author><name sortKey="Baruzzi, A" sort="Baruzzi, A" uniqKey="Baruzzi A" first="A" last="Baruzzi">A. Baruzzi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1620142</idno><idno type="pmid">1620142</idno><idno type="doi">10.1002/mds.870070310</idno><idno type="wicri:Area/PubMed/Corpus">004D31</idno><idno type="wicri:Area/PubMed/Curation">004D31</idno><idno type="wicri:Area/PubMed/Checkpoint">004D35</idno><idno type="wicri:Area/Ncbi/Merge">001459</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.</title><author><name sortKey="Contin, M" sort="Contin, M" uniqKey="Contin M" first="M" last="Contin">M. Contin</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Neuropharmacology, University of Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Laboratory of Neuropharmacology, University of Bologna</wicri:regionArea><wicri:noRegion>University of Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Riva, R" sort="Riva, R" uniqKey="Riva R" first="R" last="Riva">R. Riva</name></author><author><name sortKey="Martinelli, P" sort="Martinelli, P" uniqKey="Martinelli P" first="P" last="Martinelli">P. Martinelli</name></author><author><name sortKey="Baruzzi, A" sort="Baruzzi, A" uniqKey="Baruzzi A" first="A" last="Baruzzi">A. Baruzzi</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Benserazide (administration & dosage)</term><term>Benserazide (adverse effects)</term><term>Benserazide (pharmacokinetics)</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (adverse effects)</term><term>Carbidopa (pharmacokinetics)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Levodopa (pharmacokinetics)</term><term>Male</term><term>Middle Aged</term><term>Motor Skills (drug effects)</term><term>Motor Skills (physiology)</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (drug therapy)</term><term>Reaction Time (drug effects)</term><term>Reaction Time (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Benserazide</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Benserazide</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Benserazide</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term><term>Neurologic Examination</term><term>Reaction Time</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Motor Skills</term><term>Reaction Time</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The potential difference in the concentration-effect relationship of oral sequential doses of levodopa was explored in six Parkinsonian patients with complex fluctuating response. These patients showed "wearing-off phenomena" characterized by a transient worsening of motor function at the end of the first morning dose response to below baseline values and complained of a progressive reduction of levodopa effect during the day. A first standard levodopa dose was given in the morning, after an overnight fast and levodopa withdrawal. A second equal levodopa dose was administered immediately at the end of the first dose deterioration phase. Postimprovement worsening of motor response was also observed after the second levodopa dose in all patients. No significant difference in the pharmacokinetics of levodopa or in duration or magnitude of motor response could be appreciated between the two doses. These results further support the suggestion that, under controlled dietary conditions, plasma levodopa levels and effects relationship is reproducible between doses. Moreover, even when transient deterioration of motor function occurs between levodopa doses, the central dopaminergic system appears to remain responsive to the drug.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">1620142</PMID><DateCreated><Year>1992</Year><Month>08</Month><Day>04</Day></DateCreated><DateCompleted><Year>1992</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>1992</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>244-8</MedlinePgn></Pagination><Abstract><AbstractText>The potential difference in the concentration-effect relationship of oral sequential doses of levodopa was explored in six Parkinsonian patients with complex fluctuating response. These patients showed "wearing-off phenomena" characterized by a transient worsening of motor function at the end of the first morning dose response to below baseline values and complained of a progressive reduction of levodopa effect during the day. A first standard levodopa dose was given in the morning, after an overnight fast and levodopa withdrawal. A second equal levodopa dose was administered immediately at the end of the first dose deterioration phase. Postimprovement worsening of motor response was also observed after the second levodopa dose in all patients. No significant difference in the pharmacokinetics of levodopa or in duration or magnitude of motor response could be appreciated between the two doses. These results further support the suggestion that, under controlled dietary conditions, plasma levodopa levels and effects relationship is reproducible between doses. Moreover, even when transient deterioration of motor function occurs between levodopa doses, the central dopaminergic system appears to remain responsive to the drug.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Contin</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Neuropharmacology, University of Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Baruzzi</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>762OS3ZEJU</RegistryNumber><NameOfSubstance UI="D001545">Benserazide</NameOfSubstance></Chemical><Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber><NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001545">Benserazide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002230">Carbidopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009048">Motor Skills</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011930">Reaction Time</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1620142</ArticleId><ArticleId IdType="doi">10.1002/mds.870070310</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Baruzzi, A" sort="Baruzzi, A" uniqKey="Baruzzi A" first="A" last="Baruzzi">A. Baruzzi</name><name sortKey="Martinelli, P" sort="Martinelli, P" uniqKey="Martinelli P" first="P" last="Martinelli">P. Martinelli</name><name sortKey="Riva, R" sort="Riva, R" uniqKey="Riva R" first="R" last="Riva">R. Riva</name></noCountry><country name="Italie"><noRegion><name sortKey="Contin, M" sort="Contin, M" uniqKey="Contin M" first="M" last="Contin">M. Contin</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001459 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001459 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:1620142
|texte= Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:1620142" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |